Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell Lymphomas
Conditions: CD30-Positive Neoplastic Cells Present; Folliculotropic Mycosis Fungoides; Recurrent Mycosis Fungoides; Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome Interventions: Drug: Brentuximab Vedotin; Drug: Lenalidomide; Other: Laboratory Biomarker Analysis Sponsor: City of Hope Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cutaneous T cell lymphoma | Lymphoma | Non-Hodgkin's Lymphoma | Revlimid | T-cell Lymphoma